However, while promising, the application of siRNA-based therapy is limited by several obstacles, for example susceptibility to enzymatic degradation, difficulty of delivery to target tissues, off-target effects, etc. By using a modified PAMAM dendrimer, we knocked down Twist1, reduced the expression of EMT-related target genes, and altered the phenotypic characteristics associated with cancer cell migration and invasion. Here, TWIST1 is linked to cancer.